临床试验/CTRI/2023/10/059275

CTRI/2023/10/059275尚未招募4 期

Comparative efficacy of once daily versus twice daily insulin glargine in children with type 1 diabetes

surbhi bharti1 个研究点分布在 1 个国家目标入组 34 人开始时间: 2023年5月11日最近更新: 2023年10月26日

研究概览

简要总结

In some patient with type 1 diabetes the duration of action of glargine is 20 hrs resulting in hyperglycemia towars the end of 24 hrs hence twice daily dosing will improve glycemic control. Patients 8 to 18 years will be recruited and divided into 2 groups- glargine od versus bd to study mean difference in HbA1c levels

研究设计

研究类型: Interventional
分配方式: Random Number Table
盲法: Open Label

入排标准

年龄范围: 8.00 Year(s) 至 18.00 Year(s)（—）
性别: All

入选标准

•HbA1c >7.5 on insulin for atleast 1 year.

排除标准

•past history of recurrent severe hypoglycemia.

结局指标

主要结局

mean difference in HbA1c levels

时间窗: 3 months

次要结局

hypoglycemic episodes(3 months)

研究者

发起方

surbhi bharti

申办方类型

Other [self]

研究点 (1)

Loading locations...

相似试验

已完成

4 期

Treatment Trial Evaluating Long Acting Insulin in Type 1 DiabetesType 1 Diabetes

NCT00276393Mayo Clinic22

已完成

不适用

Late Night Snack and Insulin GlargineHypoglycemiaType 1 Diabetes

NCT02871180Diabeteszentrum Bad Lauterberg im Harz20

已完成

4 期

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) FailureType 2 Diabetes Mellitus

NCT01461577Sanofi89

终止

4 期

Insulin Glargine Versus Twice-Daily NPHType 2 Diabetes Mellitus

NCT00687453Charles Drew University of Medicine and Science27

进行中（未招募）

1 期

iraglutide in type 1 diabetes. A randomised, double-blind, placebo controlled study of the effect of liraglutide as an additional treatment to insulin on HbA1c, body weight and hypoglycaemia in poorly regulated type 1 diabetes patients.Primary objective:To investigate the effect of liraglutide 1.8 mg once daily compared to placebo for 24 weeks on change in HbA1c in patients with type 1 diabetes as an add-on therapy to insulin.Secondary objectives:To investigate the effect of liraglutide as an add-on therapy to insulin compared to placebo on change in:Weight, insulin dose,hypoglycaemic events, CGM, BMI, body composition, quality of life, treatment satisfaction,food preferences, meal test, CIMT, PWV and 24 hour blood pressure.MedDRA version: 14.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders

EUCTR2012-001150-26-DKSteno Diabetes Center